Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00344019 · ClinicalTrials.gov registry record · Phase 4
Effects of Atorvastatin on Myonecrosis
A Phase 4 study, sponsored by Beth Israel Deaconess Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 97
- Enrollment target
NCT00344019 is a Phase 4 study that was terminated before completion, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 97 participants.
The verdict
NCT00344019, a Phase 4 study, was terminated before completion, sponsored by Beth Israel Deaconess Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 97 participants
- Enrollment target
Study Summary
This study is designed as a prospective, randomized, placebo-controlled, double-blind analysis of atorvastatin 80 mg versus placebo administered on average 4 hours prior to percutaneous coronary intervention \[PCI\] (at least 2 hours) in patients presenting with unstable angina. Only patients with negative cardiac biomarkers, measured on 2 separate occasions a few hours apart will be eligible for inclusion. Furthermore, patients already on high-dose statin therapy; patients taking any statin within 24 hours prior to the PCI; and patients with contraindications to statins will be excluded from the study. The primary endpoint is a quantitative troponin level at 18-24 hours after PCI. At an enrollment of a total of 150 patients (75 per group), the study is powered to detect a 30% difference in troponin level. Secondary endpoints include elevation of creatine kinase (CK) and CK-MB above the upper limit of normal, change in C-reactive protein (CRP) levels from baseline and thrombolysis in myocardial infarction (TIMI) myocardial perfusion grade. All patients will be started on statin therapy the day after the procedure, as deemed appropriate by their treating physicians.
Interventions
- DRUG Atorvastatin 80mg
- DRUG Placebo Oral Tablet
- OTHER Screening
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2006-05 |
| Est. Completion | 2009-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00344019
The ClinicalTrials.gov registry entry for NCT00344019 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Atorvastatin 80mg is the first listed.
NCT00344019 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00344019 about?
NCT00344019 is a clinical study titled "Effects of Atorvastatin on Myonecrosis". This study is designed as a prospective, randomized, placebo-controlled, double-blind analysis of atorvastatin 80 mg versus placebo administered on average 4 hours prior to percutaneous coronary intervention \[PCI\] (at least 2 hours) in patients presenting with unstable angina. Only patients with n...
What is the current status of trial NCT00344019?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 97 participants. The study started on 2006-05. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00344019?
The interventions under investigation include: Atorvastatin 80mg (DRUG), Placebo Oral Tablet (DRUG), Screening (OTHER).
Who is sponsoring clinical trial NCT00344019?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.